The methods for sample preparation disclosed herein utilize an air phase to reduce aqueous phase associated with magnetic particles bound to nucleic acids to decrease carryover of one or more contaminants, such as, cell debris, chaotropic agents, non-specifically attached molecules, and the like. This air-transfer step is improved by using a combination of a first population of magnetic particles and a second population of magnetic particles, where the first population of magnetic particles is capable of associating with nucleic acids, and the magnetic particles in the second population are at least two-times larger in size than the size of the magnetic particles in the first population. As discussed herein, the use of this second population of magnetic particles improves the transfer of the first population of magnetic particles by reducing loss of the first magnetic particles during the transfer. The sample preparation methods may be semi-automated or completely automated.

A method and a biosensor for determination of the presence of corona-virus are provided. The method includes qualitative or quantitative measurement of probable corona-virus presence by means of colorimetric and/or electrochemical transducer methods as a result of interaction of S-protein in patient samples by means of a biosensor including ACE2, DPP4 and CD147 bio-receptors as bio-receptor.

Disclosed herein are ACE2 recombinant proteins and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such recombinant proteins.

An apparatus for photonic biosensors for multiplexed diagnostics and a method of use are disclosed. The apparatus includes a portable device configured for point-of-care diagnostics. The portable device includes a photonic sensor chip that includes one or more resonators that is substantially in contact with at least a fluid that includes one or more analytes and the reader device communicatively connected to the photonic sensor chip that includes at least a light source and the reader device is configured to provide an input optical signal using the at least a light source, receive the one or more sensor signals from the photonic sensor chip and determine one or more characteristics of the one or more analytes as a function of the one or more sensor signals and a connecting system, wherein the connecting system is configured to connect the photonic sensor chip and the reader device.

The present disclosure, in part, relates to novel, relates to novel, prognostic tools for severe COVID-19 disease, including identification of a set of clinical parameters that can be used to generate a clinical risk score of COVID-19 complications. The present disclosure also relates to proteomic panel-profiling of patients with severe COVID-19 complications versus mild-moderate symptoms to characterize biological processes and pathways associated with disease severity. Also disclosed are identified molecular changes associated with the clinical findings that can be used to generate a molecular severity score. In addition, the methods disclosed here relate to identifying effective methods of treatments based on the patient analysis.

The invention relates to a method for in vitro diagnosis of a viral infection due to the presence of a vims in a subject, comprising a step of detecting at least one antigen specific for said vims by means of an immunological test carried out on a biological sample from said subject, characterized in that said biological sample consists of a combination of saliva and secretions from the anterior nasal vestibule of the subject.

The present invention provides a rabies virus monoclonal antibody 2F2 and universal rabies virus antibody rapid detection test paper and belongs to the technical field of biological detection. An amino acid sequence of the monoclonal antibody 2F2 is shown as SEQ ID No. 1. The monoclonal antibody 2F2 provided by the present invention specifically binds to rabies virus G proteins, and preparation of the monoclonal antibody 2F2 into test paper has the advantages of rapidity, accuracy, sensitivity, specificity and low cost.

An antibody-DNA conjugate set for detection of a target protein, comprising a first antibody-DNA conjugate having a first antibody which is capable of binding to the target protein; and a first DNA oligo linked to the first antibody; a second antibody-DNA conjugate having a second antibody which is capable of binding to the target protein; and a second DNA oligo linked to the second antibody.

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.